Table 2. Subgroup analyses for the effect of oral isoflavone supplementation on endothelial thickness.
| Study number | Number of subjects | SMD1 (95%CI) | P2 | |
|---|---|---|---|---|
| Age | ||||
| ≤60y | 20 | 1931 | −0.02(−0.22,0.18) | 0.84 |
| >60y | 3 | 336 | −0.24(−0.75,0.26) | |
| Daily Isoflavone dose | ||||
| ≤54mg/d | 13 | 1183 | 0.15(−0.08,0.38) | 0.007 |
| >54mg/d | 10 | 984 | −0.26(−0.45,−0.07) | |
| Total isoflavone dose | ||||
| ≤14000mg | 12 | 767 | −0.09(−0.27,0.08) | 0.30 |
| >14000mg | 11 | 1400 | −0.02(−0.32,0.28) | |
| BMI | ||||
| ≤25kg/m2 | 11 | 1137 | 0.05(−0.24,0.35) | 0.07 |
| >25kg/m2 | 9 | 760 | −0.19(−0.40,0.01) | |
| Geographic regions | ||||
| North America | 7 | 726 | −0.04(−0.58,0.50) | 0.04 |
| South America | 2 | 156 | −0.23(−0.44,−0.01) | |
| Asia | 3 | 224 | 0.23(−0.04,0.50) | |
| Australia | 2 | 116 | −0.18(−0.62,0.26) | |
| Europe | 9 | 945 | 0.01(−0.34,0.36) |
1
SMD: standard mean difference
2
P value is from the meta-analysis of total effect of each subgroup, assessed by random-effect models